Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,455

Document Document Title
WO/2020/083871A1
The present invention relates to novel oligogalacturonans having a degree of methylation of 0 and a degree of polymerisation of 1 to 10, and to the use thereof for stimulating defence responses of plants against pathogenic microorganisms.  
WO/2020/061129A1
Disclosed herein are compositions and methods for labeling cells using click chemistry reagents. The compositions and methods disclosed herein provide a specific and efficient means of localizing desired agents to a variety of cell types...  
WO/2020/040433A1
The present invention relates to a method for preparation of a dapagliflozin precursor, which is a SGLT-2 inhibitor and, particularly, to a method for preparation of the dapagliflozin precursor, which is the compound of chemical formula ...  
WO/2020/036382A1
The present invention relates to a method for producing an intermediate useful for the synthesis of a diphenylmethane derivative that can be used as a SGLT inhibitor. A method for synthesizing a compound of formula 7 according to the pre...  
WO/2020/002076A1
The present invention relates to the cosmetic use, as moisturizer for keratin materials, preferably the skin, of one or more 5-oxazolidine-2,4-dione C-glycoside derivatives corresponding to formula (I) below, and also the solvates and/or...  
WO/2020/001812A1
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.  
WO/2020/002054A1
The present invention relates to a process for the cosmetic treatment of keratin materials, comprising the application to said materials, such as the skin, of a composition comprising a compound (I) The invention relates in particular to...  
WO/2019/151128A1
A cell labeling agent according to the present invention includes a monosaccharide derivative having a six-membered ring structure metabolized by sialic acid in a sialic acid biosynthesis pathway of a cell. Among groups bonded to carbon ...  
WO/2019/101937A3
The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics ...  
WO/2019/115616A1
The present invention relates to Novel 1,7-dicarba-closo- dodecaborane(12) (meta-carbaborane)-derived carboxylic acids suitable for peptide modification for application in boron neutron capture therapy (BNCT).  
WO/2019/115617A1
The present invention relates to Novel 1,7-dicarba-closo-dodecaborane (meta-carbaborane)-derived carboxylic acids and amines according to Formula (I) suitable for peptide modification for application in boron neutron capture therapy (BNC...  
WO/2019/106122A1
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.  
WO/2019/043069A1
The present invention relates to a new class of sucrose esters and a method for their preparation.  
WO/2018/207111A1
The present invention relates to an industrially feasible and economically viable process for preparation of SGLT2 inhibitors of formula (X) in significantly high yield and purity.  
WO/2018/163194A1
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.  
WO/2018/155970A1
The present invention relates to a novel glucose derivative, and said novel compound is useful as an SGLT-2 inhibitor. In addition, the novel glucose derivative according to the present invention has a relatively higher melting point, lo...  
WO/2018/132073A1
There is provided a β-peptido sugar-copolymer having the structure of formula (I) as defined herein, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of the same. There is provided a proce...  
WO/2018/089449A1
The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity...  
WO/2018/069490A1
A compound of formula (I) : (I) and its conjugates.  
WO/2018/032272A1
A novel method for preparing an important bioactive substance, oligomeric mannuronic diacid. The method uses oligomeric mannuronic acid as the starting material and obtains the target substance by means of steps of acid degradation and a...  
WO/2017/221211A1
The present invention provides for crystalline Dapagliflozin butane –1,2– diol solvate (VIII), crystalline Dapagliflozin (S) butane –1,2– diol solvate (VIIIa) and Dapagliflozin (R) butane –1,2– diol solvate (VIIIb). The prese...  
WO/2017/181102A1
Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiam...  
WO/2017/099496A1
The present invention relates to a novel solvate of dapagliflozin, an SGLT-2 inhibitor, and a method for preparing the same.  
WO/2017/098174A1
The present invention relates to a novel method for obtaining surfactant compositions made from alkyl-L-guluronamides or mixtures of L-guluronamides and D-mannuronamides, the compositions obtained by said method and the uses thereof.  
WO/2017/086443A1
The purpose of the present invention is to provide a 6'-sialyl lactose sodium salt (hereinafter referred to as 6SL) crystal that is easy to handle and has high preservation stability under normal and high temperature conditions and a met...  
WO/2017/085144A1
The invention relates to new compounds of formulae: Wherein: R 1 and R 2 can be independently H; a C 1 to C 6 alkyl including methyl, ethyl, propyl, butyl; aryl including phenyl, para-methoxyphenyl; or R 1, R 2 together with the carbon C...  
WO/2017/060925A1
The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)- 2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetra hydro-2H-pyran- 3,4,5-trioland its amorphous form. The invention further discloses novelco- cry...  
WO/2017/027980A1
There is provided a method for treating or preventing a Neisseria gonorrhoeae infection in a subject, comprising administering to the subject an effective amount of a compound of general formula I below or a pharmaceutical composition co...  
WO/2017/021549A1
The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X...  
WO/2016/123520A3
The invention discloses a novel process to make hydrophobic interaction between lignin and ABA-block-copolymers, providing solubilization or encapsulation of the lignin in block copolymer micellar systems and utilizing the micellar syste...  
WO/2016/121810A1
The present invention makes it possible to provide: crystals of N-acetylneuraminic acid ammonium salt anhydrate; and a method for producing crystals of N-acetylneuraminic acid ammonium salt anhydrate, the method being characterized in th...  
WO/2016/120257A1
The present invention relates to compounds and compositions for use in enhancing flavor and umami taste of food products. Particularly, the present invention relates to compounds of the general formula I) and compositions comprising them.  
WO/2016/120250A1
The present invention relates to compounds and compositions for use in enhancing flavor and umami taste of food products. Particularly, the present invention relates to compounds of the general formula (I) and compositions comprising them.  
WO/2016/077126A1
The present invention relates to certain SGLT-2 inhibitors, such as ertugliflozin or a co-crystal or a pharmaceutically acceptable salt thereof, for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellit...  
WO/2016/056907A1
Disclosed is the oxidation of uronic acids, such as galacturonic acid, to the corresponding aldaric acids, such as galactaric acid, under neutral or acidic conditions. Use is made of a supported gold catalyst. The oxidation occurs in goo...  
WO/2016/041470A1
Provided are compounds of SGLT-2 inhibitors, pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in ...  
WO/2015/191303A3
The present disclosure provides a unique methodology and protecting groups that enable synthesis of oligonucleotides having Z nucleotide in an easy, clean and site-specific fashion with high yield. In particular, the method causes little...  
WO/2016/017677A1
The present invention can provide: a crystal of an alkali metal N-acetylneuraminate anhydrate; and a method for producing a crystal of an alkali metal N-acetylneuraminate anhydrate, said method being characterized by comprising: adding o...  
WO/2015/132803A3
The present invention relates to a process for the preparation of (l S)-l,5-anhydro-l-C-[4- chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol which is represented by the following structural formula- 1 and its glycerol solvate.  
WO/2015/191303A2
The present disclosure provides a unique methodology and protecting groups that enable synthesis of oligonucleotides having Z nucleotide in an easy, clean and site-specific fashion with high yield. In particular, the method causes little...  
WO/2015/173373A1
The invention relates to a composition in aqueous solution comprising insulin in hexameric form, at least one substituted anionic compound and at least one polyanionic compound, said substituted anionic compound being formed by a discret...  
WO/2015/104658A3
Aspects of the present invention relate to process for preparation of amorphous form of dapagliflozin, amorphous solid dispersion of dapagliflozin together with one or more pharmaceutically acceptable carriers, process for its preparatio...  
WO/2015/155739A1
The present application discloses a stereoselective process for the preparation of β-C-arylglucosides that does not require the use of conventional carbohydrate protecting groups.  
WO/2015/140178A1
The present invention relates to a compound of the following formula (I): in which at least one and only one group chosen among R5, R6 and R7 is a group of the following formula: The present invention relates also to uses thereof for pre...  
WO/2015/101916A1
An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protec...  
WO/2015/075549A1
A Salacia composition described herein significantly reduces appetite, activates Hormone Sensitive Lipase, and manages a healthy lipid profile through inhibition of HMG-CoA Reductase enzyme. Salacia compositions described herein include ...  
WO/2015/044849A1
The present invention provides a process for the preparation of (1C)-2,3,4,6-tetra- O-acetyl-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D -glucitol of Formula III. The invention also provides a process for the purification of dapa...  
WO/2015/011578A1
The present invention relates to novel pharmaceutically acceptable glucuronic acid addition salt of Dasatinib (I) or its hydrate or solvate thereof. (I) The present invention further relates to the processes for preparation of the said g...  
WO/2015/007291A1
The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from Ribes preferably selected among Ribes Rubrum and Ribes nigrum; methods of manufacturing such bioactive Ribes alkaloid fractions and t...  
WO/2014/206299A1
Disclosed in the present invention is a method for preparing a liflozin drug intermediate using a microreactor, comprising: mixing compound III dissolved in an organic solvent with an organometallic reagent in a microreactor unit (L) by ...  

Matches 1 - 50 out of 1,455